Durvalumab with cisplatin and etoposide
WebThe patient underwent one cycle of induction chemotherapy with cisplatin and etoposide. Positron-emission tomography/computed tomography (PET-CT) after induction chemotherapy showed the tumor increased in size. The patient received volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) and the … WebNational Center for Biotechnology Information
Durvalumab with cisplatin and etoposide
Did you know?
WebNov 14, 2024 · Durvalumab is used to treat cancer of the lungs, bladder, or urinary tract. Durvalumab is sometimes given when the cancer has spread to other parts of the body … WebApr 11, 2024 · Two phase 3 trials evaluated the addition of programmed cell death-ligand 1 (PD-L1) inhibitor atezolizumab (IMpower133) (5, 6) or durvalumab (CASPIAN) (7, 8) to first-line chemotherapy (etoposide and cisplatin [EP]) followed by maintenance PD-L1 inhibitor in patients with ES-SCLC, and showed a significant improvement in overall survival (OS ...
WebDurvalumab (IMFINZI ®) + etoposide with either cisplatin or carboplatin is a Category 1, preferred treatment option for first-line ES-SCLC 3‡§ ES-SCLC=extensive-stage small cell lung cancer; EP=etoposide and either … Web(1) Introduction: Small cell lung cancer (SCLC) is an aggressive tumor type, accounting for about 15% of all lung cancers. Radiotherapy (RT) plays a fundamental role in both early and advanced stages. Currently, in advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based first-line …
WebMar 30, 2024 · Mar 30, 2024. Gina Columbus. The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care ... WebOct 26, 2024 · Durvalumab group: Cisplatin (75 mg/m² (BSA) D1#) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d with start at latest at beginning of cycle 3, ideally during cycle 1) and additional Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles according to …
WebMay 25, 2024 · Background: In extensive stage small-cell lung cancer (ES-SCLC) immune check-point inhibitors, atezolizumab and durvalumab, when combined with …
WebOct 31, 2024 · CASPIAN, which is being conducted at 209 sites across 23 countries, was funded by AstraZeneca, the maker of durvalumab. Durvalumab is already being used as standard therapy for patients with … irs afcWebOct 4, 2024 · First-line durvalumab plus platinum–etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known … portable indoor heater electricWebFeb 6, 2024 · Patients were randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab + etoposide and platinum-based chemotherapy (EP), durvalumab + EP or EP alone. 987 participants were randomized in the study overall. ... (80-100 mg/m^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 … irs advisory group managerWebApr 16, 2024 · In terms of trial CASPIAN, patients were assigned to receive durvalumab plus etoposide-cisplatin (EP) or etoposide-carboplatin (EC) regimen. Patients received … portable indoor heaters electricWebJun 1, 2024 · Durvalumab or placebo combined with gemcitabine and cisplatin was administered intravenously on a 21-day cycle for up to eight cycles. Durvalumab (1500 … portable indoor plant watering systemWebDec 7, 2024 · Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with poor survival, and platinum-etoposide chemotherapy is indicated as the mainstay of treatment. In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens. Methods irs advisory opinionsWebDec 7, 2024 · Background Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with poor survival, and platinum-etoposide chemotherapy is … irs advice on taxability of gift cards